Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53

Radiation Therapy and Esophageal Cancer

(2017) Ravi Shridhar et al.   Cancer Control

MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background

(2016) Zhimin Ye et al.   CANCER LETTERS

The regulation of MDM2 oncogene and its impact on human cancers

(2014) Y. Zhao et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α

(2014) Chi Zhang et al.   TUMOR BIOLOGY

Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo

(2013) Xi Yang et al.   CANCER BIOLOGY & THERAPY

Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence

(2013) Hongmei Luo et al.   LUNG CANCER

Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53

(2012) Nathalia Meireles da Costa et al.   CELL CYCLE

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis

(2011) Yan Wan et al.   BMC CANCER

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme

(2011) Ruth Villalonga-Planells et al.   PLoS One

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

(2010) A K Arya et al.   BRITISH JOURNAL OF CANCER

Regulation of XIAP Translation and Induction by MDM2 following Irradiation

(2009) Lubing Gu et al.   CANCER CELL

MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation

(2009) Wei Fu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mdm2 Promotes Genetic Instability and Transformation Independent of p53

(2008) A. Bouska et al.   MOLECULAR AND CELLULAR BIOLOGY

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53

(2008) S. Supiot et al.   MOLECULAR CANCER THERAPEUTICS